Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 4Breast Neoplasms 2Sarcoma 1Non-Squamous Non-Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Erlotinib Hydrochloride 21Bevacizumab 13Cisplatin 12Carboplatin 7Pemetrexed 6Gemcitabine 6Paclitaxel 5onartuzumab 4Docetaxel 3imgatuzumab 2sintilimab 1parsatuzumab 1lifastuzumab vedotin 1atezolizumab 1Vinorelbine 1RG-1507 monoclonal antibody 1Platinum Compounds 1Etoposide 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non-Squamous Non-Small Cell Lung Cancer × RG-1507 monoclonal antibody × Clear all
NCT00760929 2021-01-05

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Hoffmann-La Roche

Phase 2 Terminated
171 enrolled 17 charts
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡